News Focus
News Focus
icon url

JCNJ

04/24/17 10:43 AM

#295635 RE: cjgaddy #295630

meanwhile, back at the ranch, it is so frustrating to witness the 3 competing forces:

1. trying to get share price above $1.00
2. selling pressure on price due to ATM sales and need to bolster cash position for qtr end
3. company's refusal and/or negligence in failing to cut costs, shrink force/ BOD fees, exorbitant mgmt. salaries in light of share price

I'm now placing my chips on Stafford and Ronin. Hopefully they can exact some change and fiscal and fiduciary responsibility

All IMO, good luck longs
icon url

biopharm

07/26/17 5:45 AM

#305545 RE: cjgaddy #295630

Thanks CJ and just a reminder to any new investors....Dr Raymond Birge is one of the top researchers and does John Stafford / Ronin Capital Management understand that Big Pharma has not PRd these facts in a hundred years so does Big Pharma understand how important PS Targeting is? Of course they do....

Does it seem like Ronin wants to help Peregrine current shareholders more.....than their Big Pharma ties ? That I am not positive....but am positive that the letter to shareholders does not match what I read below...

Ronin has many ties and even his crew has some ties to CSM Fargo ND so no, one has to triple check the intent Ronin actually brings to the table and reading below does not mean STOPPING ANY PS Targeting collaborations

If Ronin files another SEC letter and demands to open to public all past present and pending future collaborations then he may be honest about his intent here but I doubt he will file for those facts and dozens of collaborations that may PROVE PS Targeting worth much more than Ronin leads us to believe!
___________

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer.

Birge RB1, Boeltz S2, Kumar S1, Carlson J3, Wanderley J4, Calianese D1, Barcinski M5, Brekken RA6,7, Huang X6,7, Hutchins JT3, Freimark B3, Empig C3, Mercer J8, Schroit AJ9, Schett G2, Herrmann M2.
Author information
Abstract
Apoptosis is an evolutionarily conserved and tightly regulated cell death modality. It serves important roles in physiology by sculpting complex tissues during embryogenesis and by removing effete cells that have reached advanced age or whose genomes have been irreparably damaged. Apoptosis culminates in the rapid and decisive removal of cell corpses by efferocytosis, a term used to distinguish the engulfment of apoptotic cells from other phagocytic processes. Over the past decades, the molecular and cell biological events associated with efferocytosis have been rigorously studied, and many eat-me signals and receptors have been identified. The externalization of phosphatidylserine (PS) is arguably the most emblematic eat-me signal that is in turn bound by a large number of serum proteins and opsonins that facilitate efferocytosis. Under physiological conditions, externalized PS functions as a dominant and evolutionarily conserved immunosuppressive signal that promotes tolerance and prevents local and systemic immune activation. Pathologically, the innate immunosuppressive effect of externalized PS has been hijacked by numerous viruses, microorganisms, and parasites to facilitate infection, and in many cases, establish infection latency. PS is also profoundly dysregulated in the tumor microenvironment and antagonizes the development of tumor immunity. In this review, we discuss the biology of PS with respect to its role as a global immunosuppressive signal and how PS is exploited to drive diverse pathological processes such as infection and cancer. Finally, we outline the rationale that agents targeting PS could have significant value in cancer and infectious disease therapeutics.

https://www.ncbi.nlm.nih.gov/pubmed/26915293